San Francisco, 5 March 2019: The Report Next Generation Sequencing (NGS) Market Size & Forecast By Application
(Oncology, Reproductive Health), By Technology (Targeted, WGS, WES ), By
Workflow (Data Analysis), By end-use (Academic & Clinical Research), And
Trend Analysis, 2018 - 2025
The global next
generation sequencing market is anticipated to reach USD 21.4 billion by 2025,
according to a new report by Grand View Research, Inc. Increasing coverage of
NGS is expected to drive use of precision medicine in oncology from research
based setting to clinical cancer setting. Commercial payers are also engaged in
reviewing the existing and novel tests in order to establish appropriate medical
necessity criteria for their clinical and medical policies.
Moreover,
improved understanding of the genetic markers of virulence and resistance
provided by next generation sequencing is expected to drive demand of the
technology in infectious disease diagnosis.
Access Research Report of Next Generation Sequencing Market @ www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market
Further Key Findings
from the Report suggest:
· Oncology
accounted for the dominant share owing to phase-resolved and unambiguous
results obtained by using single assay systems, and analysis program.
· Targeted
resequencing dominated the market owing to its associated benefits such as
implementation of the technique such as lower turnaround time and more
manageable data sets.
· Academic
usage of NGS accounted for the largest share with respect to market revenue by
end uses and is anticipated to maintain its dominance.
· Higher
adoption of this technology and platforms in university projects is expected to
support the estimated share.
· Asia
Pacific is estimated to witness the fastest growth over the forecast period
owing to expected routing of a considerable portion of whole genome sequencing
requirements herein.
· Key
players operating in the NGS market include Illumina Inc., Agilent
Technologies, BGI, Pacific Biosciences, Qiagen, Roche, Thermo Fischer
Scientific, and Oxford Nanopore Technologies Ltd.
· Endeavors
adopted by participants are such as acquisition of Enzymatics by Qiagen
acquired solutions in order to enhance the product portfolio with respect to
reagents needed in preparatory steps.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/biotechnology
Grand
View Research has segmented the NGS market on the basis of application,
technology, workflow, and end use:
NGS Outlook, by Application (Revenue, USD
Million; 2014 - 2025)
·
Reproductive
Health
·
Oncology
·
HLA
Typing/Immune System Monitoring
·
Metagenomics,
Epidemiology & Drug Development
·
Agrigenomics
& Forensics
·
Consumer
Genomics
·
Clinical
Investigation
NGS Outlook, by Technology (Revenue, USD
Million; 2014 - 2025)
·
Targeted
Sequencing Analysis
·
Whole
Genome Sequencing
·
Whole
Exome Sequencing
NGS Outlook, by Workflow (Revenue, USD
Million; 2014 - 2025)
·
Pre-sequencing
·
Sequencing
NGS Outlook, by End-use (Revenue, USD
Million; 2014 - 2025)
·
Academic
Research
·
Clinical
Research
·
Hospitals
& Clinics
·
Pharma
& Biotech Entities
·
Other
Users
NGS Outlook, by Region (Revenue, USD
Million; 2014 - 2025)
·
North
America
·
Europe
·
Asia
Pacific
·
Latin
America
·
Middle
East & Africa
Access Press Release of
Next Generation Sequencing Market@ www.grandviewresearch.com/press-release/global-next-generation-sequencing-market
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, we offer market
intelligence studies ensuring relevant and fact-based research across a range
of industries, from technology to chemicals, materials and healthcare.
For More Information: www.grandviewresearch.com
No comments:
Post a Comment